Previous 10 | Next 10 |
2024-03-22 13:02:29 ET More on Mid-day movers & stocks. Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Aemetis, Inc. (AMTX) Q4 2023 Earnings Call Transcript Aemetis, Inc. 2023 Q4 - Results - Earnings Call Presentation Aemetis surges after USCIS ap...
A look at the top 10 most actives in the United States Biolase Inc. (BIOL) rose 52.0% to $0.228 on volume of 76,448,685 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 8.5% to $0.1476 on volume of 32,191,096 shares Nova Lifestyle Inc (NVFY) rose 121.6% to $4.1 on volume of 32,...
2024-03-22 09:00:03 ET Gil Blum from Needham issued a price target of $15.00 for NKTX on 2024-03-22 08:17:00. The adjusted price target was set to $15.00. At the time of the announcement, NKTX was trading at $12.98. The overall price target consensus is at $34.00 with hi...
2024-03-21 16:45:19 ET More on Nkarta Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders Nkarta: Possible Upside From H1 Update, If Positive Seeking Alpha’s Quant Rating on Nkarta Historical earnings data for Nkarta Financial ...
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019 Pipeline realignment focuses...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
2024-03-19 07:29:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some overlooked stocks remain obscure and wait for astute investors to spot them. This happens even in the middle of Wall Street’s busy trading floors and the digital chaos of online inv...
2024-03-13 13:22:47 ET Summary Nkarta's stock soared 690% in six months, buoyed by promising cell therapy technology for cancer and autoimmune diseases. Financially healthy, with a high current ratio and a cash runway extending into 2026, indicating low near-term dilution risk. ...
2024-02-29 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Among tech investments, the search for the next titan resembles a deep dive into the ocean for pearls. The periodic portfolio shifts toward solid tech contenders with high-yield potential as th...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in three upcoming investor conferences: Cowen Annual Health Care Conference ...
News, Short Squeeze, Breakout and More Instantly...
Nkarta Inc. Company Name:
NKTX Stock Symbol:
NASDAQ Market:
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments Strong balance sheet, bolstered by recent $240.1 milli...
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeti...